Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Convertible Debt (2020 - 2025)

BridgeBio Pharma (BBIO) has disclosed Convertible Debt for 6 consecutive years, with $739.9 million as the latest value for Q2 2025.

  • Quarterly Convertible Debt changed 0.27% to $739.9 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $739.9 million through Jun 2025, changed 0.27% year-over-year, with the annual reading at $543.4 million for FY2023, 0.32% changed from the prior year.
  • Convertible Debt hit $739.9 million in Q2 2025 for BridgeBio Pharma, up from $563.1 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $739.9 million in Q2 2025 to a low of $539.5 million in Q3 2021.
  • Historically, Convertible Debt has averaged $645.6 million across 5 years, with a median of $731.7 million in 2021.
  • Biggest five-year swings in Convertible Debt: soared 98.35% in 2021 and later decreased 26.14% in 2022.
  • Year by year, Convertible Debt stood at $539.9 million in 2021, then rose by 0.31% to $541.6 million in 2022, then grew by 0.32% to $543.4 million in 2023, then rose by 0.25% to $544.7 million in 2024, then skyrocketed by 35.83% to $739.9 million in 2025.
  • Business Quant data shows Convertible Debt for BBIO at $739.9 million in Q2 2025, $563.1 million in Q1 2025, and $544.7 million in Q3 2024.